GNLX

Genelux Corporation (GNLX) | Rumor.io

Genelux

GNLX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,548

Bullish sentiment (50-day avg)56%

Price to earnings ratio-2.87

Market capitalization111.8M

Earnings per share-0.86

Dividend yield (TTM)—

Revenue (annual)8K

Net income (annual)-32.1M

Social

What share of all stock conversation is about GNLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Jan 8

Genelux Corporation announced a $20.0 million underwritten public offering of common stock, pricing shares at $3.00 each.
The offering includes an option for underwriters to purchase an additional 1 million shares within 30 days.
The company plans to use the funds from the offering to support its Olvi-Vec clinical trials.

Generated by AI

Sentiment

Of the messages about GNLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +66.67	83.43% -9.73
Bearish	—	—	0% -66.67	16.57% +9.73

Mar 7

$GNLX has shown a remarkable 733% increase from its IPO price of $5 to a high of $36.59.
The asset has strong support and could continue to run, with some analysts predicting it could reach $50.
$GNLX has a tightly held free float of only 2.5 million shares, which could contribute to further price increases if buying continues.

Generated by AI

Topics

Of the messages about GNLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	93.55%	83.33%
Technical Analysis	—	0%	6.45%	11.54%
Analysts	—	0%	0%	5.13%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Community

Of the messages about GNLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.83%	63.41%	72.77%
Newcomers	—	4.17%	36.59%	27.23%

Regulars· May 24

The board and CEO of Genelux Corporation have resigned following a successful proxy campaign by a hedge fund, effectively ending the sale process.
The company has announced the pricing of an underwritten offering of approximately $27.5 million, comprising 6,875,000 shares of common stock and accompanying warrants.
The company's shares have sunk by 26.1% pre-market after the underwritten public offering launched, with the stock trading at a lower price due to the sale of additional shares.

Newcomers· Mar 7

The newcomer investors are focused on the impressive price surge of $GNLX, with some posts highlighting a 265% increase since its IPO, and others noting a 433% gain from its low.
Many newcomers are speculating about the stock's future performance, with some predicting further upside and others warning about potential short squeezes.
The newcomers are also discussing the stock's volume, with some noting a significant increase and others expressing caution about the lack of real volume, and the potential for a pullback before further gains.

Generated by AI

-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t

21d agoYahoo Finance

Also Discussed

Investors talking about GNLX also mention

#	Name	Attention
1	AMAM - Ambrx Biopharma Inc.	——
2	Silo Pharma Inc.SILO	0%new
3	Veru Inc.VERU	0%0
4	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
5	Jade Biosciences Inc.AVTE	0%0
6	RAPT - RAPT Therapeutics, Inc.	——
7	Journey Medical Corp. Common StockDERM	0%0
8	Genenta Science S.p.A. Sponsored ADRGNTA	0%0
9	CytoMed Therapeutics Ltd.GDTC	0%0
10	Barnes & Noble Education Inc.BNED	0%0

Genelux Corporation

Healthcare
Biotechnology

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response. The company also advances CHOICE, a discovery and development platform, alongside a broader pipeline of engineered virus-based product candidates. Genelux serves the oncology market through drug research, development, and clinical trial services centered on immuno-oncology applications. Headquartered in Westlake Village, California, Genelux Corporation concentrates on current therapeutic programs and specialty biotechnology solutions aimed at addressing unmet needs in cancer treatment.

Website

Location

2625 Townsgate Road

Westlake Village, CA, 91361

United States

Social

What share of all stock conversation is about GNLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Jan 8

Genelux Corporation announced a $20.0 million underwritten public offering of common stock, pricing shares at $3.00 each.
The offering includes an option for underwriters to purchase an additional 1 million shares within 30 days.
The company plans to use the funds from the offering to support its Olvi-Vec clinical trials.

Generated by AI

Sentiment

Of the messages about GNLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +66.67	83.43% -9.73
Bearish	—	—	0% -66.67	16.57% +9.73

Mar 7

$GNLX has shown a remarkable 733% increase from its IPO price of $5 to a high of $36.59.
The asset has strong support and could continue to run, with some analysts predicting it could reach $50.
$GNLX has a tightly held free float of only 2.5 million shares, which could contribute to further price increases if buying continues.

Generated by AI

Topics

Of the messages about GNLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	93.55%	83.33%
Technical Analysis	—	0%	6.45%	11.54%
Analysts	—	0%	0%	5.13%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Community

Of the messages about GNLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.83%	63.41%	72.77%
Newcomers	—	4.17%	36.59%	27.23%

Regulars· May 24

The board and CEO of Genelux Corporation have resigned following a successful proxy campaign by a hedge fund, effectively ending the sale process.
The company has announced the pricing of an underwritten offering of approximately $27.5 million, comprising 6,875,000 shares of common stock and accompanying warrants.
The company's shares have sunk by 26.1% pre-market after the underwritten public offering launched, with the stock trading at a lower price due to the sale of additional shares.

Newcomers· Mar 7

The newcomer investors are focused on the impressive price surge of $GNLX, with some posts highlighting a 265% increase since its IPO, and others noting a 433% gain from its low.
Many newcomers are speculating about the stock's future performance, with some predicting further upside and others warning about potential short squeezes.
The newcomers are also discussing the stock's volume, with some noting a significant increase and others expressing caution about the lack of real volume, and the potential for a pullback before further gains.

Generated by AI

Genelux

Social

Jan 8

Sentiment

Mar 7

Topics

Community

Regulars· May 24

Newcomers· Mar 7

News

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

12 Health Care Stocks Moving In Friday's After-Market Session

Genelux chief scientific officer Yu Yong sells $26,658 of stock

Genelux CEO Zindrick sells $91,899 in common stock

Genelux CTO Joseph Cappello sells $28,112 in company stock

Benchmark reiterates Genelux stock rating on cancer therapy progress

Also Discussed

Genelux Corporation

Company Information

Location

News

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

12 Health Care Stocks Moving In Friday's After-Market Session

Genelux chief scientific officer Yu Yong sells $26,658 of stock

Genelux CEO Zindrick sells $91,899 in common stock

Genelux CTO Joseph Cappello sells $28,112 in company stock

Benchmark reiterates Genelux stock rating on cancer therapy progress

Also Discussed

Social

Jan 8

Sentiment

Mar 7

Topics

Community

Regulars· May 24

Newcomers· Mar 7